問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間：2023-09-19

陳清埤
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳清埤

List

32Cases

2014-11-01 - 2019-05-31

Phase III

A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Condition/Disease

    Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction

  • Test Drug

    LCZ696

Participate Sites
9Sites

Terminated9Sites

2014-12-01 - 2017-09-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-05-01 - 2019-03-31

Phase III

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

  • Condition/Disease

    Acute Heart Failure Patients

  • Test Drug

    REASANZ

Participate Sites
10Sites

Terminated10Sites

2011-04-01 - 2019-04-26

Phase III

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

  • Condition/Disease

    Atherosclerosis

  • Test Drug

    Canakinumab / ACZ885

Participate Sites
14Sites

Terminated14Sites

2012-09-01 - 2013-12-31

Phase III

A randomized, 8-week, double-blind, parallel-group, active controlled, multicenter study to evaluate the efficacy and safety of the combination of LCZ696 200 mg + amlodipine 5 mg in comparison with amlodipine 5 mg in patients with essential hypertension not adequately responsive to amlodipine 5 mg monotherapy treatment.

  • Condition/Disease

    essential hypertension

  • Test Drug

    LCZ696

Participate Sites
5Sites

Terminated5Sites

2012-07-01 - 2013-06-30

Phase III

A 14 week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the efficacy and safety of LCZ696 in comparison to olmesartan in elderly patients with essential hypertension

  • Condition/Disease

    Essential Hypertention

  • Test Drug

    LCZ696

Participate Sites
10Sites

Terminated10Sites

2010-03-01 - 2014-07-18

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2007-10-15 - 2008-10-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2014-06-01 - 2017-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2007-10-01 - 2008-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB